Role of VIP and PACAP in islet function

Peptides

Volumn 28, Issue 9, 2007, Pages 1805-1813

  Winzell, Maria Sörhede ^a   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Insulin secretion; Islets; PACAP; Parasympathetic; Receptor; VIP

Indexed keywords

ADENYLATE CYCLASE; ANTIDIABETIC AGENT; BAY 55 9837; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; HORMONE RECEPTOR AFFECTING AGENT; HUMAN INSULIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MAXADILAN; NEUROPEPTIDE; RO 251553; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ARTICLE; CALCIUM TRANSPORT; CELL FUNCTION; CHOLINERGIC SYSTEM; ENZYME ACTIVATION; EXTRACELLULAR CALCIUM; GENE DELETION; GLUCAGON RELEASE; GLUCOSE INTOLERANCE; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PARASYMPATHETIC NERVE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INSULIN; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SIGNAL TRANSDUCTION; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA;

EID: 34548444547     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.04.024     Document Type: Article

References (80)

1. Ahrén B., and Lundquist I. Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse. Diabetologia 20 (1981) 54-59
2. Ahrén B., Taborsky Jr. G.J., and Porte Jr. D. Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 29 (1986) 827-836
3. Ahrén B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 43 (2000) 393-410
4. Ahrén B., and Holst J.J. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes 50 (2001) 1030-1038
5. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 3 (2003) 365-372
6. Ahrén B., Holst J.J., and Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 26 (2003) 2860-2864
7. Ahrén B., and Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36 (2004) 867-876
8. Ahrén B., and Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 7 (2005) 2-8
9. Ahrén B., Wierup N., and Sundler F. Neuropeptides and the regulation of islet function. Diabetes 55 Suppl 2 (2006) S98-S107
10. Ahrén B., and Taborsky G.J. Beta cell function and insulin secretion. In: Porte Jr. D., Sherwin R.S., and Baron A. (Eds). Ellenberg & Rifkin's Diabetes Mellitus. 6th ed. (2002) 43-65
11. Ammala C., Ashcroft F.M., and Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature 363 (1993) 356-358
12. Arahira S., Kusao M., Shioda S., and Yada T. PACAP activates pancreatic alpha-cells in a glucose independent manner. Ann N Y Acad Sci 921 (2000) 438-442
13. Arimura A. Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. Jpn J Physiol 48 (1998) 301-331
14. Asnicar M.A., Koster A., Heiman M.L., Tinsley F., Smith D.P., Galbreath E., et al. Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 143 (2002) 3994-4006
15. Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57 (2006) 265-281
16. Bertrand G., Puech R., Maisonnasse Y., Bockaert J., and Loubatieres-Mariani M.M. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat. Br J Pharmacol 117 (1996) 764-770
17. Bishop A.E., Polak J.M., Green I.C., Bryant M.G., and Bloom S.R. The location of VIP in the pancreas of man and rat. Diabetologia 18 (1980) 73-78
18. Borboni P., Porzio O., Pierucci D., Cicconi S., Magnaterra R., Federici M., et al. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic beta-cells and effects of PACAP-38 on components of the insulin secretory system. Endocrinology 140 (1999) 5530-5537
19. Buscail L., Cambillau C., Seva C., Scemama J.L., De Neef P., Robberecht P., et al. Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide. Gastroenterology 103 (1992) 1002-1008
20. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
21. Carlsson P.O., Ostenson C.G., Efendic S., Langel U., and Jansson L. Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats. Regul Pept 63 (1996) 123-128
22. Chatterjee T.K., Sharma R.V., and Fisher R.A. Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels. J Biol Chem 271 (1996) 32226-32232
23. Clairmont K.B., Buckholz T.M., Pellegrino C.M., Buxton J.M., Barucci N., Bell A., et al. Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J Med Chem 49 (2006) 7545-7548
24. Edwards A.V., Bloom S.R., and Ghatei M.A. Pancreatic endocrine responses to the peptides VIP and PACAP in the conscious calf. Exp Physiol 82 (1997) 717-727
25. Eliasson L., Ma X., Renstrom E., Barg S., Berggren P.O., Galvanovskis J., et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 121 (2003) 181-197
26. Filipsson K., Tornoe K., Holst J., and Ahrén B. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J Clin Endocrinol Metab 82 (1997) 3093-3098
27. Filipsson K., and Ahrén B. Protein kinase A inhibition and PACAP-induced insulin secretion in HIT-T15 cells. Ann N Y Acad Sci 865 (1998) 441-444
28. Filipsson K., Karlsson S., and Ahrén B. Evidence for contribution by increased cytoplasmic Na+ to the insulinotropic action of PACAP38 in HIT-T15 cells. J Biol Chem 273 (1998) 32602-32607
29. Filipsson K., Pacini G., Scheurink A.J., and Ahrén B. PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am J Physiol 274 (1998) E834-E842
30. Filipsson K., Sundler F., Hannibal J., and Ahrén B. PACAP and PACAP receptors in insulin producing tissues: localization and effects. Regul Pept 74 (1998) 167-175
31. Filipsson K., Sundler F., and Ahrén B. PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion. Biochem Biophys Res Commun 256 (1999) 664-667
32. Filipsson K., Kvist-Reimer M., and Ahrén B. The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes 50 (2001) 1959-1969
33. Fridolf T., Sundler F., and Ahrén B. Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. Cell Tissue Res 269 (1992) 275-279
34. Fukushima Y., Hikichi H., Mizukami K., Nagayama T., Yoshida M., Suzuki-Kusaba M., et al. Role of endogenous PACAP in catecholamine secretion from the rat adrenal gland. Am J Physiol Regul Integr Comp Physiol 281 (2001) R1562-R1567
35. Green B.D., Irwin N., Cassidy R.S., Gault V.A., and Flatt P.R. Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice. Peptides 27 (2006) 2343-2349
36. Gromada J., Brock B., Schmitz O., and Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 95 (2004) 252-262
37. Hannibal J., and Fahrenkrug J. Pituitary adenylate cyclase-activating polypeptide in intrinsic and extrinsic nerves of the rat pancreas. Cell Tissue Res 299 (2000) 59-70
38. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., et al. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci U S A 98 (2001) 13355-13360
39. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 (2000) 1751-1760
40. Holz G.G. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53 (2004) 5-13
41. Inagaki N., Yoshida H., Mizuta M., Mizuno N., Fujii Y., Gonoi T., et al. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A 91 (1994) 2679-2683
42. Jamen F., Persson K., Bertrand G., Rodriguez-Henche N., Puech R., Bockaert J., et al. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105 (2000) 1307-1315
43. Jamen F., Puech R., Bockaert J., Brabet P., and Bertrand G. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC. Endocrinology 143 (2002) 1253-1259
44. Jansson L. The regulation of pancreatic islet blood flow. Diabetes Metab Rev 10 (1994) 407-416
45. Jansson L. Vasoactive intestinal polypeptide increases whole pancreatic blood flow but does not affect islet blood flow in the rat. Acta Diabetol 31 (1994) 103-106
46. Kato I., Suzuki Y., Akabane A., Yonekura H., Tanaka O., Kondo H., et al. Transgenic mice overexpressing human vasoactive intestinal peptide (VIP) gene in pancreatic beta cells. Evidence for improved glucose tolerance and enhanced insulin secretion by VIP and PHM-27 in vivo. J Biol Chem 269 (1994) 21223-21228
47. Kawai K., Ohse C., Watanabe Y., Suzuki S., Yamashita K., and Ohashi S. Pituitary adenylate cyclase activating polypeptide stimulates insulin release from the isolated perfused rat pancreas. Life Sci 50 (1992) 257-261
48. Kawai K., Yokota C., Ohashi S., Isobe K., Suzuki S., Nakai T., et al. Pituitary adenylate cyclase-activating polypeptide: effects on pancreatic-adrenal hormone secretion and glucose-lipid metabolism in normal conscious dogs. Metabolism 43 (1994) 739-744
49. Klinteberg K.A., Karlsson S., and Ahrén B. Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells. Endocrinology 137 (1996) 2791-2798
50. Kulkarni R.N., Smith D.M., Ghatei M.A., and Bloom S.R. A 67 kDa protein mediates pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide-stimulated insulin secretion in a hamster clonal beta-cell line. J Endocrinol 147 (1995) 121-130
51. Laburthe M., Couvineau A., and Marie J.C. VPAC receptors for VIP and PACAP. Receptors Channels 8 (2002) 137-153
52. Leech C.A., Holz G.G., and Habener J.F. Signal transduction of PACAP and GLP-1 in pancreatic beta cells. Ann N Y Acad Sci 805 (1996) 81-92
53. Lu N., Zhou R., and DiCicco-Bloom E. Opposing mitogenic regulation by PACAP in sympathetic and cerebral cortical precursors correlates with differential expression of PACAP receptor (PAC1-R) isoforms. J Neurosci Res 53 (1998) 651-662
54. Meyer D.K. The effects of PACAP on neural cell proliferation. Regul Pept 137 (2006) 50-57
55. Pan C.Q., Li F., Tom I., Wang W., Dumas M., Froland W., et al. Engineering novel VPAC2 selective agonists with improved stability and glucose lowering activity in vivo. J Pharmacol Exp Ther 320 (2006) 900-906
56. Persson-Sjogren S., Forsgren S., and Lindstrom P. Vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide: effects on insulin release in isolated mouse islets in relation to metabolic status and age. Neuropeptides 40 (2006) 283-290
57. Persson K., and Ahrén B. The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. Acta Physiol Scand 175 (2002) 25-28
58. Portela-Gomes G.M., Lukinius A., Ljungberg O., Efendic S., Ahrén B., and Abdel-Halim S.M. PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept 113 (2003) 31-39
59. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60 (2000) 3105-3112
60. Schafer H., Zheng J., Gundlach F., Gunther R., Siegel E.G., Folsch U.R., et al. Pituitary adenylate-cyclase-activating polypeptide stimulates proto-oncogene expression and activates the AP-1 (c-Fos/c-Jun) transcription factor in AR4-2J pancreatic carcinoma cells. Eur J Biochem 242 (1996) 467-476
61. Sekiguchi Y., Kasai K., Hasegawa K., Suzuki Y., and Shimoda S. Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro. Life Sci 55 (1994) 1219-1228
62. Sherwood N.M., Krueckl S.L., and McRory J.E. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21 (2000) 619-670
63. Shintani N., Tomimoto S., Hashimoto H., Kawaguchi C., and Baba A. Functional roles of the neuropeptide PACAP in brain and pancreas. Life Sci 74 (2003) 337-343
64. Shioda S., Zhou C.J., and Ohtaki H. PACAP receptor signaling. In: Vaudry H., and Mrimura A. (Eds). Pituitary adenylate cyclase activating polypeptide (2003), Kluwer Academic Publishers, Dordrecht 95-124
65. Shioda S., Ohtaki H., Nakamachi T., Dohi K., Watanabe J., Nakajo S., et al. Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann N Y Acad Sci 1070 (2006) 550-560
66. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365 (1993) 170-175
67. Straub S.G., and Sharp G.W. Mechanisms of action of VIP and PACAP in the stimulation of insulin release. Ann N Y Acad Sci 805 (1996) 607-612
68. Taborsky Jr. G.J., Ahrén B., and Havel P.J. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 47 (1998) 995-1005
69. Tornoe K., Hannibal J., Fahrenkrug J., and Holst J.J. PACAP-(1-38) as neurotransmitter in pig pancreas: receptor activation revealed by the antagonist PACAP-(6-38). Am J Physiol 273 (1997) G436-G446
70. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., Zhu J., et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 (2002) 1453-1460
71. Usdin T.B., Bonner T.I., and Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 (1994) 2662-2680
72. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
73. Vilsboll T., and Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47 (2004) 357-366
74. Yada T., Sakurada M., Ihida K., Nakata M., Murata F., Arimura A., et al. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269 (1994) 1290-1293
75. Yada T., Sakurada M., Ishihara H., Nakata M., Shioda S., Yaekura K., et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J Physiol 505 Pt 2 (1997) 319-328
76. Yada T., Sakurada M., Filipsson K., Kikuchi M., and Ahrén B. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. Ann N Y Acad Sci 921 (2000) 259-263
77. Yamada H., Watanabe M., and Yada T. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors. Regul Pept 123 (2004) 147-153
78. Yamamoto K., Hashimoto H., Tomimoto S., Shintani N., Miyazaki J., Tashiro F., et al. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52 (2003) 1155-1162
79. Yokota C., Kawai K., Ohashi S., Watanabe Y., and Yamashita K. PACAP stimulates glucose output from the perfused rat liver. Peptides 16 (1995) 55-60
80. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., Fenyk-Melody J.E., et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 278 (2003) 22418-22423